Compare NRC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRC | TRDA |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 481.6M |
| IPO Year | 1997 | 2021 |
| Metric | NRC | TRDA |
|---|---|---|
| Price | $17.76 | $14.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 68.9K | ★ 158.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ 4707.69 | N/A |
| EPS | ★ 50.00 | N/A |
| Revenue | ★ $119,686,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $50.80 |
| P/E Ratio | $0.34 | ★ N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $9.76 | $4.93 |
| 52 Week High | $22.79 | $14.49 |
| Indicator | NRC | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 58.33 |
| Support Level | $16.64 | $10.84 |
| Resistance Level | $18.18 | $13.99 |
| Average True Range (ATR) | 0.73 | 0.74 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 87.60 | 77.09 |
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.